Nautilus gets funding to support migraine drug launch

New Jersey's Nautilus Neurosciences has received an undisclosed investment from Galen Partners to support commercialization of its migraine treatment Cambia, which is set to launch in the first half of this year. The company was founded in November 2009 and with the help of funding from Tailwind Capital. Nautilus also has a second drug candidate--PRO-571 for acute pain--in clinical trials.

"Over the past six months we have raised approximately $25 million," says James Fares, chairman and CEO Nautilus Neurosciences. "With the backing of Tailwind, Galen, and our management team, we are confident that Nautilus is poised to become a leading neurology-focused specialty pharmaceutical company."

- here's the release on Nautilus' round

Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.